Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNM1 | Q05193 | 8/20 | 0.50 |
| ▸ | CA12 | O43570 | 2/20 | 0.50 |
| ▸ | CA1 | P00915 | 2/20 | 0.50 |
| ▸ | CA2 | P00918 | 2/20 | 0.50 |
| ▸ | CA3 | P07451 | 2/20 | 0.50 |
| ▸ | CA4 | P22748 | 2/20 | 0.50 |
| ▸ | CA6 | P23280 | 2/20 | 0.50 |
| ▸ | CA5A | P35218 | 2/20 | 0.50 |
| ▸ | CA7 | P43166 | 2/20 | 0.50 |
| ▸ | CA9 | Q16790 | 2/20 | 0.50 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.50 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.50 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | BLM | P54132 | 1/20 | 0.50 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1959776 | 1.00 | DNM1 (0.50) | DNM1CA12CA1CA2CA3 | |
| SCHEMBL8811124 | 1.00 | DNM1 (0.50) | DNM1CA12CA1CA2CA3 | |
| SCHEMBL1960836 | 1.00 | DNM1 (0.50) | DNM1CA12CA1CA2CA3 | |
| SCHEMBL8812186 | 1.00 | DNM1 (0.50) | DNM1CA12CA1CA2CA3 | |
| SCHEMBL666946 | 1.00 | DNM1 (0.50) | DNM1CA12CA1CA2CA3 | |
| SCHEMBL186389 | 1.00 | — | — | |
| SCHEMBL98073 | 1.00 | — | — | |
| SCHEMBL8812602 | 1.00 | DNM1 (0.50) | DNM1CA12CA1CA2CA3 | |
| SCHEMBL465588 | 1.00 | DNM1 (0.50) | DNM1CA12CA1CA2CA3 | |
| SCHEMBL8812125 | 1.00 | DNM1 (0.50) | DNM1CA12CA1CA2CA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 180 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118021978-A | GHRH antagonists for use in methods of treating sarcoidosis | 迈阿密大学 | 2024-05-14 | — | — | CN | claimed |
| EP-4331674-A2 | GHRH ANTAGONISTS FOR USE IN A METHOD OF TREATING SARCOIDOSIS | University of Miami (US) | 2024-03-06 | — | — | EP | claimed |
| EP-3999095-B1 | GHRH ANTAGONISTS FOR USE IN A METHOD OF TREATING SARCOIDOSIS | UNIV MIAMI (US) | 2023-09-13 | — | — | EP | claimed |
| WO-2023288316-A1 | METHOD OF USE FOR APOE PEPTIDES | ANJI PHARMA (US) LLC (US) | 2023-01-19 | — | — | WO | claimed |
| EP-3999095-A1 | GHRH ANTAGONISTS FOR USE IN A METHOD OF TREATING SARCOIDOSIS | University of Miami (US) | 2022-05-25 | — | — | EP | claimed |
| US-20220143149-A1 | GHRH ANTAGONISTS FOR USE IN A METHOD OF TREATING SARCOIDOSIS | THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS | 2022-05-12 | — | — | US | claimed |
| CN-114126653-A | GHRH antagonists for use in methods of treating sarcoidosis | 迈阿密大学 | 2022-03-01 | — | — | CN | claimed |
| CN-112851755-A | Linear lipopeptide compound and preparation method and application thereof | 中国人民解放军军事科学院军事医学研究院 | 2021-05-28 | — | — | CN | claimed |
| WO-2021011874-A1 | GHRH ANTAGONISTS FOR USE IN A METHOD OF TREATING SARCOIDOSIS | UNIVERSITY OF MIAMI (US) | 2021-01-21 | — | — | WO | claimed |
| US-20200276273-A1 | METHOD FOR TREATING MYELOID LEUKEMIA | THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS | 2020-09-03 | — | — | US | claimed |
| US-10653747-B2 | ApoE mimetic peptides and higher potency to clear plasma cholesterol | UAB RESEARCH FOUNDATION (US) | 2020-05-19 | — | — | US | claimed |
| WO-2019060601-A1 | METHOD FOR TREATING MYELOID LEUKEMIA | UNIVERSITY OF MIAMI (US) | 2019-03-28 | — | — | WO | claimed |
| CN-107074923-A | APOE simulating peptides and the more efficient power to removing plasma cholesterol | UAB研究基金会 | 2017-08-18 | — | — | CN | claimed |
| US-20170209537-A1 | APOE MIMETIC PEPTIDES AND HIGHER POTENCY TO CLEAR PLASMA CHOLESTEROL | LIPIMETIX DEVELOPMENT, INC. | 2017-07-27 | — | — | US | claimed |
| EP-3189069-A1 | APOE MIMETIC PEPTIDES AND HIGHER POTENCY TO CLEAR PLASMA CHOLESTEROL | UAB Research Foundation (US) | 2017-07-12 | — | — | EP | claimed |
| WO-2016018665-A1 | APOE MIMETIC PEPTIDES AND HIGHER POTENCY TO CLEAR PLASMA CHOLESTEROL | UAB RESEARCH FOUNDATION (US) | 2016-02-04 | — | — | WO | claimed |
| US-6545131-B1 | Splitting drug with prostate specific antigen; activation of drug; antiproliferative agents | THE JOHNS HOPKINS UNIVERSITY | 2003-04-08 | — | — | US | claimed |
| WO-2001093861-A1 | TISSUE SPECIFIC PRODRUG | THE JOHN HOPKINS UNIVERSITY (US) | 2001-12-13 | — | — | WO | claimed |
| EP-0428849-A2 | Retroviral protease inhibitors | HOECHST AKTIENGESELLSCHAFT (DE) | 1991-05-29 | — | — | EP | claimed |
| CN-118021978-A | GHRH antagonists for use in methods of treating sarcoidosis | 迈阿密大学 | 2024-05-14 | — | — | CN | disclosed |
| EP-4331674-A2 | GHRH ANTAGONISTS FOR USE IN A METHOD OF TREATING SARCOIDOSIS | University of Miami (US) | 2024-03-06 | — | — | EP | disclosed |
| CN-114126653-B | GHRH antagonists for use in methods of treating sarcoidosis | 迈阿密大学 | 2024-02-20 | — | — | CN | disclosed |
| EP-3999095-B1 | GHRH ANTAGONISTS FOR USE IN A METHOD OF TREATING SARCOIDOSIS | UNIV MIAMI (US) | 2023-09-13 | — | — | EP | disclosed |
| WO-2023288316-A1 | METHOD OF USE FOR APOE PEPTIDES | ANJI PHARMA (US) LLC (US) | 2023-01-19 | — | — | WO | disclosed |
| EP-3999095-A1 | GHRH ANTAGONISTS FOR USE IN A METHOD OF TREATING SARCOIDOSIS | University of Miami (US) | 2022-05-25 | — | — | EP | disclosed |
| US-20220143149-A1 | GHRH ANTAGONISTS FOR USE IN A METHOD OF TREATING SARCOIDOSIS | THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS | 2022-05-12 | — | — | US | disclosed |
| CN-114126653-A | GHRH antagonists for use in methods of treating sarcoidosis | 迈阿密大学 | 2022-03-01 | — | — | CN | disclosed |
| EP-3218395-B1 | TREATMENT OF HORMONAL DISORDERS OF GROWTH | US HEALTH (US) | 2022-01-05 | — | — | EP | disclosed |
| CN-107074923-B | APOE mimetics and higher potency for the removal of plasma cholesterol | UAB研究基金会 | 2021-08-03 | — | — | CN | disclosed |
| CN-112851755-A | Linear lipopeptide compound and preparation method and application thereof | 中国人民解放军军事科学院军事医学研究院 | 2021-05-28 | — | — | CN | disclosed |
| WO-2021011874-A1 | GHRH ANTAGONISTS FOR USE IN A METHOD OF TREATING SARCOIDOSIS | UNIVERSITY OF MIAMI (US) | 2021-01-21 | — | — | WO | disclosed |
| US-20200276273-A1 | METHOD FOR TREATING MYELOID LEUKEMIA | THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS | 2020-09-03 | — | — | US | disclosed |
| US-10653747-B2 | ApoE mimetic peptides and higher potency to clear plasma cholesterol | UAB RESEARCH FOUNDATION (US) | 2020-05-19 | — | — | US | disclosed |
| US-10555987-B2 | GHRH agonists for the treatment of ischemic disorders | UNIVERSITY OF MIAMI (US) | 2020-02-11 | — | — | US | disclosed |
| US-20190314459-A1 | TREATMENT OF HORMONAL DISORDERS OF GROWTH | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVIC (US) | 2019-10-17 | — | — | US | disclosed |
| US-10350273-B2 | Treatment of hormonal disorders of growth | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2019-07-16 | — | — | US | disclosed |
| WO-2019060601-A1 | METHOD FOR TREATING MYELOID LEUKEMIA | UNIVERSITY OF MIAMI (US) | 2019-03-28 | — | — | WO | disclosed |
| EP-2935317-B1 | GHRH AGONISTS FOR ISLET CELL TRANSPLANTATION AND FUNCTION AND THE TREATMENT OF DIABETES | UNIV MIAMI (US) | 2019-03-27 | — | — | EP | disclosed |
| EP-2794647-B1 | NOVEL GH-RH ANALOGS WITH POTENT AGONISTIC EFFECTS | UNIV MIAMI (US) | 2019-03-27 | — | — | EP | disclosed |
| EP-2934565-B1 | GHRH AGONISTS FOR THE TREATMENT OF ISCHEMIC DISORDERS | UNIV MIAMI (US) | 2019-03-13 | — | — | EP | disclosed |
| US-10201588-B2 | Materials and methods of treating dyslipidemia | UNIVERSITY OF MIAMI (US) | 2019-02-12 | — | — | US | disclosed |
| US-20180250358-A1 | GHRH AGONISTS FOR THE TREATMENT OF ISCHEMIC DISORDERS | UNIVERSITY OF MIAMI | 2018-09-06 | — | — | US | disclosed |
| EP-2175863-B1 | SUBSTITUTED NUCLEOSIDE DERIVATIVES WITH ANTIVIRAL AND ANTIMICROBIAL PROPERTIES | EASTERN VIRGINIA MEDICAL SCHOOL (US) | 2018-03-21 | — | — | EP | disclosed |
| US-9855312-B2 | GHRH agonists for the treatment of ischemic disorders | UNIVERSITY OF MIAMI (US) | 2018-01-02 | — | — | US | disclosed |
| US-20170304405-A1 | TREATMENT OF HORMONAL DISORDERS OF GROWTH | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN (US) | 2017-10-26 | — | — | US | disclosed |
| EP-3218395-A1 | TREATMENT OF HORMONAL DISORDERS OF GROWTH | The United States of America, as represented by The Secretary, Department of Health and Human Services (US) | 2017-09-20 | — | — | EP | disclosed |
| US-9738678-B2 | Substituted nucleoside derivatives with antiviral and antimicrobial properties | EASTERN VIRGINIA MEDICAL SCHOOL (US) | 2017-08-22 | — | — | US | disclosed |
| CN-107074923-A | APOE simulating peptides and the more efficient power to removing plasma cholesterol | UAB研究基金会 | 2017-08-18 | — | — | CN | disclosed |
| US-20170209537-A1 | APOE MIMETIC PEPTIDES AND HIGHER POTENCY TO CLEAR PLASMA CHOLESTEROL | LIPIMETIX DEVELOPMENT, INC. | 2017-07-27 | — | — | US | disclosed |
| US-20170202907-A1 | Materials and Methods of Treating Dyslipidemia | UNIVERSITY OF MIAMI (US) | 2017-07-20 | — | — | US | disclosed |
| EP-3189069-A1 | APOE MIMETIC PEPTIDES AND HIGHER POTENCY TO CLEAR PLASMA CHOLESTEROL | UAB Research Foundation (US) | 2017-07-12 | — | — | EP | disclosed |
| EP-2288374-B1 | NOVEL N-AND C-TERMINAL SUBSTITUTED ANTAGONISTIC ANALOGS OF HUMAN GH-RH | THE UNIV OF MIAMI (US) | 2017-02-01 | — | — | EP | disclosed |
| US-20160311843-A1 | SUBSTITUTED NUCLEOSIDE DERIVATIVES WITH ANTIVIRAL AND ANTIMICROBIAL PROPERTIES | EASTERN VIRGINIA MEDICAL SCHOOL (US) | 2016-10-27 | — | — | US | disclosed |
| US-9453063-B2 | Hybrid polypeptides with selectable properties | AMYLIN PHARMACEUTICALS, LLC. (US) | 2016-09-27 | — | — | US | disclosed |
| US-9393271-B2 | GHRH agonists for islet cell transplantation and function and the treatment of diabetes | UNIVERSITY OF MIAMI (US) | 2016-07-19 | — | — | US | disclosed |
| US-20160166652-A1 | NOVEL N- AND C-TERMINAL SUBSTITUTED ANTAGONISTIC ANALOGS OF GH-RH | UNIV MIAMI (US) | 2016-06-16 | — | — | US | disclosed |
| WO-2016077620-A1 | TREATMENT OF HORMONAL DISORDERS OF GROWTH | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2016-05-19 | — | — | WO | disclosed |
| US-9296776-B2 | Substituted nucleoside derivatives with antiviral and antimicrobial properties | EASTERN VIRGINIA MEDICAL SCHOOL (US) | 2016-03-29 | — | — | US | disclosed |
| US-9260504-B2 | N- and C-terminal substituted antagonistic analogs of GH-RH | UNIVERSITY OF MIAMI (US) | 2016-02-16 | — | — | US | disclosed |
| WO-2016018665-A1 | APOE MIMETIC PEPTIDES AND HIGHER POTENCY TO CLEAR PLASMA CHOLESTEROL | UAB RESEARCH FOUNDATION (US) | 2016-02-04 | — | — | WO | disclosed |
| EP-2934565-A2 | GHRH AGONISTS FOR THE TREATMENT OF ISCHEMIC DISORDERS | University of Miami (US) | 2015-10-28 | — | — | EP | disclosed |
| EP-2935317-A2 | GHRH AGONISTS FOR ISLET CELL TRANSPLANTATION AND FUNCTION AND THE TREATMENT OF DIABETES | University of Miami (US) | 2015-10-28 | — | — | EP | disclosed |
| US-20150274798-A1 | NOVEL GH-RH ANALOGS WITH POTENT AGONISTIC EFFECTS | UNIV MIAMI (US) | 2015-10-01 | — | — | US | disclosed |
| US-20150265572-A1 | INJECTABLE CANCER COMPOSITIONS | GENSPERA, INC. (US) | 2015-09-24 | — | — | US | disclosed |
| US-9133260-B2 | GIP analog and hybrid polypeptides with selectable properties | AMYLIN PHARMACEUTICALS, LLC (US) | 2015-09-15 | — | — | US | disclosed |
| EP-2908838-A2 | INJECTABLE CANCER COMPOSITIONS | Genspera, Inc. (US) | 2015-08-26 | — | — | EP | disclosed |
| US-9079974-B2 | GH-RH analogs with potent agonistic effects | THE UNIVERSITY OF MIAMI (US) | 2015-07-14 | — | — | US | disclosed |
| WO-2015100423-A2 | METHODS FOR TREATING CANCER WITH GHRH AGONISTS | UNIVERSITY OF MIAMI (US) | 2015-07-02 | — | — | WO | disclosed |
| US-20150174207-A1 | METHODS FOR TREATING CANCER WITH GHRH AGONISTS | UNIV MIAMI (US) | 2015-06-25 | — | — | US | disclosed |
| US-20150166617-A1 | COMPOSITIONS AND METHODS OF TREATING ALZHEIMER'S DISEASE | THE UNIVERSITY OF MIAMI | 2015-06-18 | — | — | US | disclosed |
| EP-2866894-A2 | COMPOSITIONS AND METHODS OF TREATING ALZHEIMER'S DISEASE | The University Of Miami (US) | 2015-05-06 | — | — | EP | disclosed |
| EP-2330124-B1 | Hybrid polypeptides with selectable properties | AMYLIN PHARMACEUTICALS LLC (US) | 2015-02-25 | — | — | EP | disclosed |
| US-8895498-B2 | GIP and exendin hybrid polypeptides | ASTRAZENECA PHARMACEUTICALS, LP (US) | 2014-11-25 | — | — | US | disclosed |
| US-20140249299-A1 | HYBRID POLYPEPTIDES WITH SELECTABLE PROPERTIES | ASTRAZENECA PHARMACEUTICALS LP (US) | 2014-09-04 | — | — | US | disclosed |
| EP-2478011-B1 | FLUORINATED GHRH ANTAGONISTS | UNIV MIAMI (US) | 2014-08-27 | — | — | EP | disclosed |
| US-8796330-B2 | Inhibitors of histone deacetylase and prodrugs thereof | METHYLGENE INC. (CA) | 2014-08-05 | — | — | US | disclosed |
| US-20140206836-A1 | NOVEL N- AND C-TERMINAL SUBSTITUTED ANTAGONISTIC ANALOGS OF GH-RH | U.S.A., REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS (US) | 2014-07-24 | — | — | US | disclosed |
| US-20140193378-A1 | GHRH AGONISTS FOR ISLET CELL TRANSPLANTATION AND FUNCTION AND THE TREATMENT OF DIABETES | UNIVERSITY OF MIAMI (US) | 2014-07-10 | — | — | US | disclosed |
| US-8772226-B2 | Methods and compositions for the detection of cancer | THE JOHNS HOPKINS UNIVERSITY (US) | 2014-07-08 | — | — | US | disclosed |
| WO-2014100816-A2 | GHRH AGONISTS FOR ISLET CELL TRANSPLANTATION AND FUNCTION AND THE TREATMENT OF DIABETES | UNIVERSITY OF MIAMI (US) | 2014-06-26 | — | — | WO | disclosed |
| WO-2014100809-A2 | GHRH AGONISTS FOR THE TREATMENT OF ISCHEMIC DISORDERS | UNIVERSITY OF MIAMI (US) | 2014-06-26 | — | — | WO | disclosed |
| US-20140179604-A1 | GHRH AGONISTS FOR THE TREATMENT OF ISCHEMIC DISORDERS | U.S.A., REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS (US) | 2014-06-26 | — | — | US | disclosed |
| US-8759400-B2 | Histone deacetylase inhibitors for enhancing activity of antifungal agents | METHYLGENE INC. (CA) | 2014-06-24 | — | — | US | disclosed |
| US-8716242-B2 | β-hairpin peptidomimetics | POLYPHOR AG (CH) | 2014-05-06 | — | — | US | disclosed |
| WO-2014062587-A2 | INJECTABLE CANCER COMPOSITIONS | GENSPERA, INC. (US) | 2014-04-24 | — | — | WO | disclosed |
| US-8697647-B2 | Hybrid polypeptides with selectable properties | ASTRAZENECA PHARMACEUTICALS LP | 2014-04-15 | — | — | US | disclosed |
| US-20140087991-A1 | PEPTIDE PRODRUGS | THE JOHNS HOPKINS UNIVERSITY (US) | 2014-03-27 | — | — | US | disclosed |
| US-20140081017-A1 | Histone Deacetylase Inhibitors for Enhancing Activity of Antifungal Agents | METHYLGENE INC. (CA) | 2014-03-20 | — | — | US | disclosed |
| US-8669231-B2 | Activation of peptide prodrugs by hK2 | GENSPERA, INC. (US) | 2014-03-11 | — | — | US | disclosed |
| US-20140058068-A1 | Novel GH-RH analogs with potent agonistic effects | UNITED STATES OF AMERICA, REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS | 2014-02-27 | — | — | US | disclosed |
| US-20140024608-A1 | INHIBITORS OF HISTONE DEACETYLASE AND PRODRUGS THEREOF | METHYLGENE INC. (CA) | 2014-01-23 | — | — | US | disclosed |
| WO-2014004934-A2 | COMPOSITIONS AND METHODS OF TREATING ALZHEIMER'S DISEASE | UNIVERSITY OF MIAMI (US) | 2014-01-03 | — | — | WO | disclosed |
| US-8598314-B2 | Peptide-peptidase-inhibitor conjugates and methods of making and using same | AMYLIN PHARMACEUTICALS, LLC (US) | 2013-12-03 | — | — | US | disclosed |
| US-20130281374-A1 | DPP-IV RESISTANT GIP HYBRID POLYPEPTIDES WITH SELECTABLE PROPERTIES | ASTRAZENECA PHARMACEUTICALS LP (US) | 2013-10-24 | — | — | US | disclosed |
| US-20130261055-A1 | Novel N- and C- terminal substituted antagonistic analogs of GH-RH | MIAMI, UNIVERSITY OF | 2013-10-03 | — | — | US | disclosed |
| US-20130196913-A1 | GIP ANALOG AND HYBRID POLYPEPTIDES WITH SELECTABLE PROPERTIES | ASTRAZENECA PHARMACEUTICALS LP (US) | 2013-08-01 | — | — | US | disclosed |
| EP-2057188-B1 | DPP-IV RESISTANT GIP HYBRID POLYPEPTIDES WITH SELECTABLE PROPERTIES | AMYLIN PHARMACEUTICALS LLC (US) | 2013-07-31 | — | — | EP | disclosed |
| US-8497240-B2 | DPP-IV resistant GIP hybrid polypeptides with selectable properties | AMYLIN PHARMACEUTICALS, LLC (US) | 2013-07-30 | — | — | US | disclosed |
| US-20130137631-A1 | GIP ANALOG AND HYBRID POLYPEPTIDES WITH SELECTABLE PROPERTIES | AMYLIN PHARMACEUTICALS, LLC (US) | 2013-05-30 | — | — | US | disclosed |
| US-8450280-B2 | Activation of peptide prodrugs by hK2 | GenbSpera, Inc. (US) | 2013-05-28 | — | — | US | disclosed |
| EP-1718665-B1 | HYBRID POLYPEPTIDES WITH SELECTABLE PROPERTIES | AMYLIN PHARMACEUTICALS LLC (US) | 2013-04-10 | — | — | EP | disclosed |
| US-8404637-B2 | GIP analog and hybrid polypeptides with selectable properties | AMYLIN PHARMACEUTICALS, LLC (US) | 2013-03-26 | — | — | US | disclosed |
| US-20120309692-A1 | Activation of Peptide Prodrugs by hK2 | INSPYR THERAPEUTICS, INC. | 2012-12-06 | — | — | US | disclosed |
| EP-1922336-B1 | HYBRID POLYPEPTIDES WITH SELECTABLE PROPERTIES | AMYLIN PHARMACEUTICALS LLC (US) | 2012-11-21 | — | — | EP | disclosed |
| US-20120283166-A1 | PEPTIDE PRODRUGS | THE JOHNS HOPKINS UNIVERSITY (US) | 2012-11-08 | — | — | US | disclosed |
| US-20120283196-A1 | BETA-HAIRPIN PEPTIDOMIMETICS | POLYPHOR AG (CH) | 2012-11-08 | — | — | US | disclosed |
| US-20120253023-A1 | HYBRID POLYPEPTIDES WITH SELECTABLE PROPERTIES | AMYLIN PHARMACEUTICALS, INC. (US) | 2012-10-04 | — | — | US | disclosed |
| US-8263545-B2 | GIP analog and hybrid polypeptides with selectable properties | AMYLIN PHARMACEUTICALS, INC. (US) | 2012-09-11 | — | — | US | disclosed |
| US-8258256-B2 | Compositions and methods for the treatment of cancer | THE JOHNS HOPKINS UNIVERSITY (US) | 2012-09-04 | — | — | US | disclosed |
| EP-2478011-A1 | FLUORINATED GHRH ANTAGONISTS | University of Miami (US) | 2012-07-25 | — | — | EP | disclosed |
| US-8227405-B2 | Fluorinated GHRH antagonists | UNIVERSITY OF MIAMI (US) | 2012-07-24 | — | — | US | disclosed |
| US-8227421-B2 | Fluorinated GHRH antagonists | UNIVERSITY OF MIAMI (US) | 2012-07-24 | — | — | US | disclosed |
| US-20120093724-A1 | METHODS AND COMPOSITIONS FOR THE DETECTION OF CANCER | THE JOHNS HOPKINS UNIVERSITY (US) | 2012-04-19 | — | — | US | disclosed |
| EP-2422806-A2 | Hybrid polypeptides with selectable properties | Amylin Pharmaceuticals Inc. (US) | 2012-02-29 | — | — | EP | disclosed |
| EP-2422807-A2 | Hybrid polypeptides with selectable properties | Amylin Pharmaceuticals Inc. (US) | 2012-02-29 | — | — | EP | disclosed |
| US-20120046331-A1 | Antifungal Agents and Uses Thereof | METHYLGENE INC. (CA) | 2012-02-23 | — | — | US | disclosed |
| EP-2417980-A1 | Hybrid polypeptides with selectable properties | Amylin Pharmaceuticals Inc. (US) | 2012-02-15 | — | — | EP | disclosed |
| EP-2408465-A2 | METHODS AND COMPOSITIONS FOR THE DETECTION OF CANCER | The Johns Hopkins University (US) | 2012-01-25 | — | — | EP | disclosed |
| US-8076288-B2 | Hybrid polypeptides having glucose lowering activity | AMYLIN PHARMACEUTICALS, INC. (US) | 2011-12-13 | — | — | US | disclosed |
| EP-2392595-A1 | GIP analog and hybrid polypeptides with selectable properties | Amylin Pharmaceuticals Inc. (US) | 2011-12-07 | — | — | EP | disclosed |
| EP-2390264-A1 | GIP analog and hybrid polypeptides with selectable propperties | Amylin Pharmaceuticals Inc. (US) | 2011-11-30 | — | — | EP | disclosed |
| US-20110258488-A1 | Server Failure Recovery | MICROSOFT CORPORATION (US) | 2011-10-20 | — | — | US | disclosed |
| US-20110245147-A1 | Activation of Peptide Prodrugs by HK2 | INSPYR THERAPEUTICS, INC. | 2011-10-06 | — | — | US | disclosed |
| WO-2011066869-A1 | BETA-HAIRPIN PEPTIDOMIMETICS | POLYPHOR AG (CH) | 2011-06-09 | — | — | WO | disclosed |
| US-20110136737-A1 | DPP-IV Resistant GIP Hybrid Polypeptides with Selectable Properties | AMYLIN PHARMACEUTICALS, INC. (US) | 2011-06-09 | — | — | US | disclosed |
| EP-2330125-A2 | Hybrid polypeptides with selectable properties | Amylin Pharmaceuticals, Inc. (US) | 2011-06-08 | — | — | EP | disclosed |
| EP-2330124-A2 | Hybrid polypeptides with selectable properties | Amylin Pharmaceuticals Inc. (US) | 2011-06-08 | — | — | EP | disclosed |
| WO-2011034976-A1 | FLUORINATED GHRH ANTAGONISTS | UNIVERSITY OF MIAMI (US) | 2011-03-24 | — | — | WO | disclosed |
| US-20110066230-A1 | Fluorinated GHRH Antagonists | UNIVERSITY OF MIAMI (GU) | 2011-03-17 | — | — | US | disclosed |
| US-7906477-B2 | Activation of peptide prodrugs by hK2 | GENSPERA, INC. (US) | 2011-03-15 | — | — | US | disclosed |
| EP-2288374-A2 | NOVEL N-AND C-TERMINAL SUBSTITUTED ANTAGONISTIC ANALOGS OF HUMAN GH-RH | The University of Miami (US) | 2011-03-02 | — | — | EP | disclosed |
| US-20110039798-A1 | SUBSTITUTED NUCLEOSIDE DERIVATIVES WITH ANTIVIRAL AND ANTIMICROBIAL PROPERTIES | EASTERN VIRGINIA MEDICAL SCHOOL (US) | 2011-02-17 | — | — | US | disclosed |
| US-20100286365-A1 | PEPTIDE-PEPTIDASE-INHIBITOR CONJUGATES AND METHODS OF MAKING AND USING SAME | AMYLIN PHARMACEUTICALS, INC. (US) | 2010-11-11 | — | — | US | disclosed |
| WO-2010107909-A2 | METHODS AND COMPOSITIONS FOR THE DETECTION OF CANCER | THE JOHNS HOPKINS UNIVERSITY (US) | 2010-09-23 | — | — | WO | disclosed |
| EP-2195034-A2 | PEPTIDE-PEPTIDASE INHIBITOR CONJUGATES AND METHODS OF MAKING AND USING SAME | Amylin Pharmaceuticals, Inc. (US) | 2010-06-16 | — | — | EP | disclosed |
| EP-2175863-A2 | SUBSTITUTED NUCLEOSIDE DERIVATIVES WITH ANTIVIRAL AND ANTIMICROBIAL PROPERTIES | Eastern Virginia Medical School (US) | 2010-04-21 | — | — | EP | disclosed |
| US-20100092539-A1 | Fluorinated GHRH Antagonists | UNITED STATES OF AMERICA REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS | 2010-04-15 | — | — | US | disclosed |
| US-20100047170-A1 | Peptide Prodrugs | JOHNS HOPKINS UNIVERSITY, THE | 2010-02-25 | — | — | US | disclosed |
| US-20090286723-A1 | Hybrid Polypeptides with Selectable Properties | AMYLIN PHARMACEUTICALS, INC. (US) | 2009-11-19 | — | — | US | disclosed |
| US-20090274625-A1 | Compositions and Methods for The Treatment of Cancer | THE JOHNS HOPKINS UNIVERSITY (US) | 2009-11-05 | — | — | US | disclosed |
| WO-2009120831-A2 | NOVEL N-AND C-TERMINAL SUBSTITUTED ANTAGONISTIC ANALOGS OF GH-RH | THE UNIVERSITY OF MIAMI (US) | 2009-10-01 | — | — | WO | disclosed |
| EP-2057188-A2 | DPP-IV RESISTANT GIP HYBRID POLYPEPTIDES WITH SELECTABLE PROPERTIES | Amylin Pharmaceuticals, Inc. (US) | 2009-05-13 | — | — | EP | disclosed |
| WO-2009042922-A2 | PEPTIDE-PEPTIDASE INHIBITOR CONJUGATES AND METHODS OF MAKING AND USING SAME | AMYLIN PHARMACEUTICALS, INC. (US) | 2009-04-02 | — | — | WO | disclosed |
| US-20090036364-A1 | GIP ANALOG AND HYBRID POLYPEPTIDES WITH SELECTABLE PROPERTIES | AMYLIN PHARMACEUTICALS, INC. (US) | 2009-02-05 | — | — | US | disclosed |
| WO-2009009625-A2 | SUBSTITUTED NUCLEOSIDE DERIVATIVES WITH ANTIVIRAL AND ANTIMICROBIAL PROPERTIES | EASTERN VIRGINIA MEDICAL SCHOOL (US) | 2009-01-15 | — | — | WO | disclosed |
| US-20080312157-A1 | GIP ANALOG AND HYBRID POLYPEPTIDES WITH SELECTABLE PROPERTIES | AMYLIN PHARMACEUTICALS, INC. (US) | 2008-12-18 | — | — | US | disclosed |
| US-20080247950-A1 | Activation of peptide prodrugs by hK2 | GENSPERA, INC. (US) | 2008-10-09 | — | — | US | disclosed |
| EP-1961424-A1 | Activation of peptide prodrugs by HK2 | The John Hopkins University (US) | 2008-08-27 | — | — | EP | disclosed |
| US-20080146623-A1 | INHIBITORS OF HISTONE DEACETYLASE AND PRODRUGS THEREOF | METHYLGENE INC. (CA) | 2008-06-19 | — | — | US | disclosed |
| EP-1922336-A2 | HYBRID POLYPEPTIDES WITH SELECTABLE PROPERTIES | Amylin Pharmaceuticals, Inc. (US) | 2008-05-21 | — | — | EP | disclosed |
| EP-1718665-A4 | HYBRID POLYPEPTIDES WITH SELECTABLE PROPERTIES | AMYLIN PHARMACEUTICALS INC (US) | 2008-05-14 | — | — | EP | disclosed |
| WO-2008021560-A2 | DPP-IV RESISTANT GIP HYBRID POLYPEPTIDES WITH SELECTABLE PROPERTIES | AMYLIN PHARMACEUTICALS, INC. (US) | 2008-02-21 | — | — | WO | disclosed |
| EP-1853627-A2 | GIP ANALOG AND HYBRID POLYPEPTIDES WITH SELECTABLE PROPERTIES | Amylin Pharmaceuticals, Inc. (US) | 2007-11-14 | — | — | EP | disclosed |
| US-20070197550-A1 | Histone deacetylase inhibitors for enhancing activity of antifungal agents | 92229129 QUEBEC INC. (CA) | 2007-08-23 | — | — | US | disclosed |
| WO-2007087131-A2 | PEPTIDE PRODRUGS | THE JOHNS HOPKINS UNIVERSITY (US) | 2007-08-02 | — | — | WO | disclosed |
| WO-2007081751-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER | THE JOHNS HOPKINS UNIVERSITY (US) | 2007-07-19 | — | — | WO | disclosed |
| WO-2007022123-A2 | HYBRID POLYPEPTIDES WITH SELECTABLE PROPERTIES | AMYLIN PHARMACEUTICALS, INC. (US) | 2007-02-22 | — | — | WO | disclosed |
| US-20060293232-A1 | Hybrid polypeptides with selectable properties | AMYLIN PHARMACEUTICALS, INC. (US) | 2006-12-28 | — | — | US | disclosed |
| EP-1718665-A2 | HYBRID POLYPEPTIDES WITH SELECTABLE PROPERTIES | Amylin Pharmaceuticals, Inc. (US) | 2006-11-08 | — | — | EP | disclosed |
| US-20060217317-A1 | Activation of peptide prodrugs by hk2 | INSPYR THERAPEUTICS, INC. | 2006-09-28 | — | — | US | disclosed |
| EP-1575995-A4 | ACTIVATION OF PEPTIDE PRODRUGS BY HK2 | UNIV JOHNS HOPKINS (US) | 2006-08-30 | — | — | EP | disclosed |
| WO-2006086769-A2 | GIP ANALOG AND HYBRID POLYPEPTIDES WITH SELECTABLE PROPERTIES | AMYLIN PHARMACEUTICALS, INC. (US) | 2006-08-17 | — | — | WO | disclosed |
| US-20060183689-A1 | Activation of peptide prodrugs by hK2 | Denmeade, Samuel (US) | 2006-08-17 | — | — | US | disclosed |
| US-20060121083-A1 | Anti-microbial medical implants and uses thereof | TECHNION RESEARCH & DEVELOPMENT FOUNDATION LTD. (IL) | 2006-06-08 | — | — | US | disclosed |
| US-7053042-B1 | Activation of peptide prodrugs by hK2 | Denmeade, Samuel (US) | 2006-05-30 | — | — | US | disclosed |
| US-20060094652-A1 | Hybrid polypeptides with selectable properties | AMYLIN PHARMACEUTICALS, INC. | 2006-05-04 | — | — | US | disclosed |
| EP-1575995-A2 | ACTIVATION OF PEPTIDE PRODRUGS BY HK2 | The Johns Hopkins University (US) | 2005-09-21 | — | — | EP | disclosed |
| WO-2005077072-A2 | HYBRID POLYPEPTIDES WITH SELECTABLE PROPERTIES | AMYLIN PHARMACEUTICALS, INC. (US) | 2005-08-25 | — | — | WO | disclosed |
| WO-2005006938-A2 | ANTI-MICROBIAL MEDICAL IMPLANTS AND USES THEREOF | TECHNION RESEARCH & DEVELOPMENT FOUNDATION LTD. (IL) | 2005-01-27 | — | — | WO | disclosed |
| WO-2004046169-A2 | ACTIVATION OF PEPTIDE PRODRUGS BY HK2 | THE JOHNS HOPKINS UNIVERSITY (US) | 2004-06-03 | — | — | WO | disclosed |
| EP-1274723-A4 | ACTIVATION OF PEPTIDE PRODRUGS BY hK2 | UNIV JOHNS HOPKINS (US) | 2003-10-01 | — | — | EP | disclosed |
| US-6545131-B1 | Splitting drug with prostate specific antigen; activation of drug; antiproliferative agents | THE JOHNS HOPKINS UNIVERSITY | 2003-04-08 | — | — | US | disclosed |
| EP-1274723-A2 | ACTIVATION OF PEPTIDE PRODRUGS BY hK2 | THE JOHNS HOPKINS UNIVERSITY (US) | 2003-01-15 | — | — | EP | disclosed |
| WO-2001093861-A1 | TISSUE SPECIFIC PRODRUG | THE JOHN HOPKINS UNIVERSITY (US) | 2001-12-13 | — | — | WO | disclosed |
| WO-2001009165-A2 | ACTIVATION OF PEPTIDE PRODRUGS BY hK2 | THE JOHNS HOPKINS UNIVERSITY (US) | 2001-02-08 | — | — | WO | disclosed |
| US-5712417-A | Inhibitors of retroviral proteases | ABBOTT LABORATORIES (US) | 1998-01-27 | — | — | US | disclosed |
| US-5691319-A | ANTICARCINOGENIC AGENTS | SANKYO COMPANY, LIMITED (JP) | 1997-11-25 | — | — | US | disclosed |
| EP-0536936-B1 | Pyrimidine nucleoside derivatives having anti-tumor activity, their preparation and use | SANKYO CO (JP) | 1996-08-14 | — | — | EP | disclosed |
| EP-0536936-A1 | Pyrimidine nucleoside derivatives having anti-tumor activity, their preparation and use | Sankyo Company Limited (JP) | 1993-04-14 | — | — | EP | disclosed |
| EP-0428849-A2 | Retroviral protease inhibitors | HOECHST AKTIENGESELLSCHAFT (DE) | 1991-05-29 | — | — | EP | disclosed |
| EP-0428849-A2 | Retroviral protease inhibitors | HOECHST AKTIENGESELLSCHAFT (DE) | 1991-05-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (30 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140081017-A1 | Histone Deacetylase Inhibitors for Enhancing Activity of Antifungal Agents | HDAC1, HDAC5, HDAC7 | DNM1 4577/4885CA12 658/4885CA1 292/4885 |
| US-20070197550-A1 | Histone deacetylase inhibitors for enhancing activity of antifungal agents | HDAC1, HDAC5, HDAC7 | DNM1 3092/4885CA12 2006/4885CA1 2057/4885 |
| US-20140087991-A1 | PEPTIDE PRODRUGS | FAP, DNPEP, FIBP | DNM1 4197/4885CA12 1921/4885CA1 2658/4885 |
| US-20120093724-A1 | METHODS AND COMPOSITIONS FOR THE DETECTION OF CANCER | KLK3, KLK2, KLK5 | DNM1 4809/4885CA12 19/4885CA1 94/4885 |
| US-20170209537-A1 | APOE MIMETIC PEPTIDES AND HIGHER POTENCY TO CLEAR PLASMA CHOLESTEROL | APOB, LDLR, APOL1 | DNM1 1342/4885CA12 4682/4885CA1 4734/4885 |
| US-20060293232-A1 | Hybrid polypeptides with selectable properties | IAPP, IGFBP1, PGF | DNM1 239/4885CA12 3979/4885CA1 4465/4885 |
| US-20150174207-A1 | METHODS FOR TREATING CANCER WITH GHRH AGONISTS | GHSR, GHRHR, GNRHR | DNM1 2180/4885CA12 768/4885CA1 624/4885 |
| US-20080312157-A1 | GIP ANALOG AND HYBRID POLYPEPTIDES WITH SELECTABLE PROPERTIES | GIPR, GLP1R, VIP | DNM1 273/4885CA12 3994/4885CA1 3930/4885 |
| US-20130196913-A1 | GIP ANALOG AND HYBRID POLYPEPTIDES WITH SELECTABLE PROPERTIES | GIPR, GLP1R, VIP | DNM1 273/4885CA12 3994/4885CA1 3930/4885 |
| US-20090286723-A1 | Hybrid Polypeptides with Selectable Properties | IAPP, IGFBP1, PGF | DNM1 239/4885CA12 3979/4885CA1 4465/4885 |
| US-20110136737-A1 | DPP-IV Resistant GIP Hybrid Polypeptides with Selectable Properties | GIPR, DPP4, GLP1R | DNM1 564/4885CA12 3903/4885CA1 3721/4885 |
| US-20090036364-A1 | GIP ANALOG AND HYBRID POLYPEPTIDES WITH SELECTABLE PROPERTIES | GIPR, GLP1R, VIP | DNM1 273/4885CA12 3994/4885CA1 3930/4885 |
| US-20120283196-A1 | BETA-HAIRPIN PEPTIDOMIMETICS | CXCL12, CXCR4, CXCR1 | DNM1 3697/4885CA12 790/4885CA1 2045/4885 |
| US-20110039798-A1 | SUBSTITUTED NUCLEOSIDE DERIVATIVES WITH ANTIVIRAL AND ANTIMICROBIAL PROPERTIES | SAMHD1, TLR3, MAVS | DNM1 757/4885CA12 4460/4885CA1 4766/4885 |
| US-20140249299-A1 | HYBRID POLYPEPTIDES WITH SELECTABLE PROPERTIES | IAPP, IGFBP1, PGF | DNM1 239/4885CA12 3979/4885CA1 4465/4885 |
| US-20130281374-A1 | DPP-IV RESISTANT GIP HYBRID POLYPEPTIDES WITH SELECTABLE PROPERTIES | GIPR, DPP4, GLP1R | DNM1 564/4885CA12 3903/4885CA1 3721/4885 |
| US-20080247950-A1 | Activation of peptide prodrugs by hK2 | HK2, HK1, KLK2 | DNM1 3856/4885CA12 997/4885CA1 1765/4885 |
| US-20160311843-A1 | SUBSTITUTED NUCLEOSIDE DERIVATIVES WITH ANTIVIRAL AND ANTIMICROBIAL PROPERTIES | SAMHD1, TLR3, MAVS | DNM1 757/4885CA12 4460/4885CA1 4766/4885 |
| US-10653747-B2 | ApoE mimetic peptides and higher potency to clear plasma cholesterol | APOB, LDLR, APOL1 | DNM1 1342/4885CA12 4682/4885CA1 4734/4885 |
| US-20120309692-A1 | Activation of Peptide Prodrugs by hK2 | HK2, HK1, KLK2 | DNM1 3856/4885CA12 997/4885CA1 1765/4885 |
| US-20120283166-A1 | PEPTIDE PRODRUGS | FAP, DNPEP, FIBP | DNM1 4197/4885CA12 1921/4885CA1 2658/4885 |
| US-20120046331-A1 | Antifungal Agents and Uses Thereof | PRKDC, PIK3C3, KRT18 | DNM1 2611/4885CA12 1030/4885CA1 2585/4885 |
| US-20120253023-A1 | HYBRID POLYPEPTIDES WITH SELECTABLE PROPERTIES | IAPP, IGFBP1, PGF | DNM1 239/4885CA12 3979/4885CA1 4465/4885 |
| US-20080146623-A1 | INHIBITORS OF HISTONE DEACETYLASE AND PRODRUGS THEREOF | HDAC1, HDAC3, HDAC11 | DNM1 4126/4885CA12 1244/4885CA1 648/4885 |
| US-20060183689-A1 | Activation of peptide prodrugs by hK2 | HK2, HK1, KLK2 | DNM1 3856/4885CA12 997/4885CA1 1765/4885 |
| US-20130137631-A1 | GIP ANALOG AND HYBRID POLYPEPTIDES WITH SELECTABLE PROPERTIES | GIPR, GLP1R, VIP | DNM1 273/4885CA12 3994/4885CA1 3930/4885 |
| US-20060094652-A1 | Hybrid polypeptides with selectable properties | IAPP, IGFBP1, PGF | DNM1 239/4885CA12 3979/4885CA1 4465/4885 |
| US-20100047170-A1 | Peptide Prodrugs | FAP, DNPEP, FIBP | DNM1 4197/4885CA12 1921/4885CA1 2658/4885 |
| US-20140024608-A1 | INHIBITORS OF HISTONE DEACETYLASE AND PRODRUGS THEREOF | HDAC1, HDAC3, HDAC11 | DNM1 4126/4885CA12 1244/4885CA1 648/4885 |
| US-20100286365-A1 | PEPTIDE-PEPTIDASE-INHIBITOR CONJUGATES AND METHODS OF MAKING AND USING SAME | DNPEP, PEPD, VIP | DNM1 2092/4885CA12 1710/4885CA1 1121/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.